Is Keros Therapeutics, Inc. (KROS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.5% / 30% | 162.6% / 30% | 1.3% / 30% | 634.99% / 5% | ✗ NOT HALAL |
| DJIM | 5.5% / 33% | 162.6% / 33% | 1.3% / 33% | 634.99% / 5% | ✗ NOT HALAL |
| MSCI | 3.1% / 33% | 90.9% / 33% | 0.7% / 33% | 634.99% / 5% | ✗ NOT HALAL |
| S&P | 5.5% / 33% | 162.6% / 33% | 1.3% / 33% | 634.99% / 5% | ✗ NOT HALAL |
| FTSE | 3.1% / 33% | 90.9% / 33% | 0.7% / 50% | 634.99% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 47.9% | |
| Operating Margin | -7576.6% | |
| Net Margin | 35.7% | |
| Return on Equity (ROE) | 19.9% | |
| Return on Assets (ROA) | 9.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $108M |
| Free Cash Flow | $106M |
| Total Debt | $17M |
| Debt-to-Equity | 5.6 |
| Current Ratio | 15.5 |
| Total Assets | $338M |
Price & Trading
| Last Close | $11.08 |
| 50-Day MA | $15.03 |
| 200-Day MA | $15.83 |
| Avg Volume | 406K |
| Beta | 0.9 |
|
52-Week Range
$9.12
| |
About Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Keros Therapeutics, Inc. (KROS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Keros Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Keros Therapeutics, Inc.'s debt ratio?
Keros Therapeutics, Inc.'s debt ratio is 5.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.1%.
What are Keros Therapeutics, Inc.'s key financial metrics?
Keros Therapeutics, Inc. has a market capitalization of $323M, trailing P/E ratio of 4.6, and revenue of $244M. The company maintains a gross margin of 47.9% and a net margin of 35.7%. Return on equity stands at 19.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.